Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving clinical data—highlighting the shift toward a comprehensive, multiphase approach that begins with a 4-drug induction regimen and stem cell transplant, as supported by the PERSEUS trial’s promising long-term remission outcomes.

Those who took dexamethasone reported higher levels of satisfaction than patients on placebo.

Panitumumab plus FOLFIRINOX or mFOLFOX6 failed to yield meaningful responses in liver-limited, RAS/BRAF wild-type unresectable mCRC.

Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures including dexamethasone premedication and dermatologic support, helps patients successfully tolerate amivantamab plus lazertinib therapy while maintaining treatment adherence.

Panelists discuss how real-world experience with amivantamab plus lazertinib has shown remarkable responses consistent with trial data, including effectiveness in challenging cases such as leptomeningeal disease, with manageable adverse effects when proper prophylactic measures and patient education are implemented.

Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even in cases of CRS.

For patients who have progressed on endocrine therapy, consistent monitoring of blood counts and biomarker testing informs treatment sequencing.

Irpagratinib plus atezolizumab showed durable responses and manageable safety in advanced HCC with FGF19 overexpression, regardless of prior ICI exposure.

Treatment with Temferon led to prolonged survival and possible disease control in 2 patients with newly diagnosed glioblastoma multiforme.

KN026 plus KN046 produced sustained responses and showed a manageable safety profile in pretreated patients with HER2-positive advanced breast cancer.

The selective internal radiation therapy SIR-Spheres has been approved by the FDA for use in patients with unresectable hepatocellular carcinoma.

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how incidental back pain led to an unexpected cancer diagnosis, the initial shock and fear that followed, and the pivotal role of expert care, accurate information, and community support in finding hope and navigating the disease.

Panelists highlight that being a care partner is one of the most challenging roles, requiring emotional resilience, coordination, and support, and emphasize the importance of viewing it as a true partnership that addresses both patient and caregiver well-being throughout the cancer journey.

Volumetric PET biomarkers may help predict risk of toxicity from CAR T-cell therapy in patients with large B-cell lymphoma, new retrospective data suggest.

Gedatolisib-based combinations yielded encouraging responses in patients with mCRPC and HER2-positive metastatic breast cancer, early trial data show.

CAR T-cell therapy is starting to enter treatment conversations sooner with patients with multiple myeloma, according to Nick Barkemeyer, PA-C, MMS.

Sunvozertinib has received accelerated approval for use in advanced or metastatic non–small lung cancer harboring EGFR exon 20 insertion mutations.

The FDA has given accelerated approval to the BiTE, linvoseltamab, for use in the fifth line of therapy for relapsed/refractory multiple myeloma.

Oncologic therapies approved in June included indications in genitourinary, lung, hematologic, and head and neck cancers.

ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma.

Anlotinib combined with immune checkpoint inhibitors may benefit patients with extensive-stage small cell lung cancer treated with prior immunotherapy.

Panelists discuss how both amivantamab plus lazertinib and osimertinib-based regimens show good central nervous system (CNS) activity for patients with baseline brain metastases, with treatment choice influenced more by patient-specific factors such as bleeding risk and anticoagulation contraindications than by CNS efficacy differences.

Panelists discuss how the MARIPOSA study findings demonstrated significant progression-free survival and overall survival benefits with amivantamab plus lazertinib vs osimertinib monotherapy, with mature overall survival data showing a 25% improvement in survival outcomes.

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, APRN-BC.